Image analysis-derived metrics of histomorphological complexity predicts prognosis and treatment response in stage II-III colon cancer

被引:20
|
作者
Mezheyeuski, Artur [1 ,2 ]
Hrynchyk, Ina [3 ]
Karlberg, Mia [1 ]
Portyanko, Anna [2 ]
Egevad, Lars [1 ]
Ragnhammar, Peter [1 ]
Edler, David [4 ]
Glimelius, Bengt [5 ]
Ostman, Arne [1 ]
机构
[1] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden
[2] Belarusian State Med Univ, Dept Pathol, Minsk, BELARUS
[3] City Clin Pathologoanat Bur, Minsk, BELARUS
[4] Karolinska Univ Hosp Solna, Dept Mol Med & Surg, Stockholm, Sweden
[5] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden
来源
SCIENTIFIC REPORTS | 2016年 / 6卷
基金
瑞典研究理事会;
关键词
THYMIDYLATE SYNTHASE EXPRESSION; COLORECTAL-CANCER; ADJUVANT THERAPY; MISMATCH REPAIR; FLUOROURACIL; CHEMOTHERAPY; INTERFACE; PATTERN; BENEFIT; MARKER;
D O I
10.1038/srep36149
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The complexity of tumor histomorphology reflects underlying tumor biology impacting on natural course and response to treatment. This study presents a method of computer-aided analysis of tissue sections, relying on multifractal (MF) analyses, of cytokeratin-stained tumor sections which quantitatively evaluates of the morphological complexity of the tumor-stroma interface. This approach was applied to colon cancer collection, from an adjuvant treatment randomized study. Metrics obtained with the method acted as independent markers for natural course of the disease, and for benefit of adjuvant treatment. Comparative analyses demonstrated that MF metrics out-performed standard histomorphological features such as tumor grade, budding and configuration of invasive front. Notably, the MF analyses-derived "alpha(max)" -metric constitutes the first response-predictive biomarker in stage II-III colon cancer showing significant interactions with treatment in analyses using a randomized trial-derived study population. Based on these results the method appears as an attractive and easy-to-implement tool for biomarker identification.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Co-expression of CXCR4 and CD133 proteins is associated with poor prognosis in stage II-III colon cancer patients
    Zhang, Nian-Hua
    Li, Jie
    Li, Yin
    Zhang, Xin-Tao
    Liao, Wen-Ting
    Zhang, Jun-Yi
    Li, Rung
    Luo, Rong-Cheng
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2012, 3 (06) : 973 - 982
  • [42] Blood parameters score predicts long-term outcomes in stage II-III gastric cancer patients
    Lin, Jian-Xian
    Tang, Yi-Hui
    Wang, Jia-Bin
    Lu, Jun
    Chen, Qi-Yue
    Cao, Long-Long
    Lin, Mi
    Tu, Ru-Hong
    Huang, Chang-Ming
    Li, Ping
    Zheng, Chao-Hui
    Xie, Jian-Wei
    WORLD JOURNAL OF GASTROENTEROLOGY, 2019, 25 (41) : 6258 - 6272
  • [43] Postoperative management of stage II/III colon cancer: A decision analysis
    Michel, P
    Merle, V
    Chiron, A
    Ducrotte, P
    Paillot, B
    Hecketsweiler, P
    Czernichow, P
    Colin, R
    GASTROENTEROLOGY, 1999, 117 (04) : 784 - 793
  • [44] Tailoring adjuvant chemotherapy by circulating tumor DNA (ctDNA) in older patients with stage II-III colon cancer
    Akagunduz, Baran
    Guven, Deniz Can
    Ozer, Muhammet
    Okten, Ilker Nihat
    Atag, Elif
    Unek, Ilkay Tugba
    Tatli, Ali Murat
    Karaoglu, Aziz
    JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (02)
  • [45] Administration of adjuvant chemotherapy for stage II-III colon cancer patients: An European population-based study
    Babaei, Masoud
    Balavarca, Yesilda
    Jansen, Lina
    Lemmens, Valery
    van Erning, Felice N.
    van Eycken, Liesbet
    Vaes, Evelien
    Sjovall, Annika
    Glimelius, Bengt
    Ulrich, Cornelia M.
    Schrotz-King, Petra
    Brenner, Hermann
    INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (07) : 1480 - 1489
  • [46] Racial and Socioeconomic Treatment Disparities in Adolescents and Young Adults with Stage II-III Rectal Cancer
    Lee, David Y.
    Teng, Annabelle
    Pedersen, Rose C.
    Tavangari, Farees R.
    Attaluri, Vikram
    McLemore, Elisabeth C.
    Stern, Stacey L.
    Bilchik, Anton J.
    Goldfarb, Melanie R.
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (02) : 311 - 318
  • [47] Effect of oncological treatment on serum adipocytokine levels in patients with stage II-III breast cancer
    Coskun, Teoman
    Kosova, Funda
    Ari, Zeki
    Sakarya, Aslan
    Kaya, Yavuz
    MOLECULAR AND CLINICAL ONCOLOGY, 2016, 4 (05) : 893 - 897
  • [48] Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patientsdA pooled analysis of three adjuvant trials
    Christou, Niki
    Bergen, Elisabeth S.
    Canton, Clemence
    Le Malicot, Karine
    Di Bartolomeo, Maria
    Galli, Fabio G.
    Galli, Francesca
    Labianca, Roberto
    Shi, Qian
    Alberts, Steven R.
    Goldberg, Richard M.
    Lepage, Come
    Sinicrope, Frank A.
    Taieb, Julien
    EUROPEAN JOURNAL OF CANCER, 2022, 166 : 100 - 111
  • [49] Chemoradiation with raltitrexed (Tomudex) in preoperative treatment of stage II-III resectable rectal cancer:: A phase II study
    Gambacorta, MA
    Valentini, V
    Morganti, AG
    Mantini, G
    Miccichè, F
    Ratto, C
    Di Miceli, D
    Rotondi, F
    Alfieri, S
    Doglietto, GB
    Vargas, JG
    De Paoli, A
    Rossi, C
    Cellini, N
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : 130 - 138
  • [50] Chromosome 18q allelic loss and prognosis in stage II and III colon cancer
    Lanza, G
    Matteuzzi, M
    Gafá, R
    Orvieto, E
    Maestri, I
    Santini, A
    del Senno, L
    INTERNATIONAL JOURNAL OF CANCER, 1998, 79 (04) : 390 - 395